Relmada Therapeutics (RLMD) Total Liabilities (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Total Liabilities data on file, last reported at $16.6 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $16.6 million, up 217.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.6 million (up 217.44% YoY), and the FY2025 annual result was $7.5 million, down 27.24% from the prior year.
• Total Liabilities grew to $16.6 million in Q1 2026 per RLMD's latest filing, from $7.5 million in the prior quarter.
• Over five years, Total Liabilities peaked at $20.8 million in Q3 2022 and troughed at $5.2 million in Q2 2025.
• A 5-year average of $11.1 million and a median of $10.3 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities plunged 59.46% in 2023, then soared 217.44% in 2026.
• A 5-year view of Total Liabilities shows it stood at $12.5 million in 2022, then fell by 2.2% to $12.2 million in 2023, then declined by 15.57% to $10.3 million in 2024, then retreated by 27.24% to $7.5 million in 2025, then surged by 121.99% to $16.6 million in 2026.
• Business Quant data shows RLMD's Total Liabilities at $16.6 million in Q1 2026, $7.5 million in Q4 2025, and $5.4 million in Q3 2025.